Colloid fluids

Perioperative Fluid Therapy

Volumn , Issue , 2016, Pages 153-162

  Dubois, Marc Jacques ^a   Vincent, Jean Louis ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052177842     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (70)

1. Arfors KE, Buckley PB. Pharmacological characteristics of artificial colloids. Bailliere's Clin Anaesth 1997; 11:15-47.
2. Vincent JL. Fluid management: the pharmacoeconomic dimension. Crit Care 2000; 4(suppl 2):S33-S35.
3. Lewis RT. Albumin: role and discriminative use in surgery. Can J Surg 1980; 23:322-328.
4. Weil MH, Henning RJ, Puri VK. Colloid oncotic pressure: clinical significance. Crit Care Med 1979; 7:113-116.
5. Soni N. Wonderful albumin? Br Med J 1995; 310:887-888.
6. Schnitzer JE, Carley WW, Palade GE. Specific albumin binding to microvascular endothelium in culture. Am J Physiol 1988; 254:H425-H427.
7. Hauser CJ, Shoemaker WC, Turpin I. Oxygen transport responses to colloids and crystalloids in critically ill surgical patients. Surg Gynecol Obstet 1980; 150:811-816.
8. Lamke LO, Liljedahl SO. Plasma volume expansion after infusion of 5%, 20%, and 25% albumin solutions in patients. Resuscitation 1976; 5:85-92.
9. Tullis JL, Albumin I. Background and use. JAMA 1977; 237:355-360.
10. Driscoll DF, McMahon M, Blackburn GL, Bistrian BR. Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations. Crit Care Med 1988; 16:1248-1249.
11. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994; 105:602-604.
12. Mimoz O, Soreda S, Padoin C, Tod M, Petitjean O, Benhamou D. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology 2000; 93:735-743.
13. Garaceni P, Gasbarrini A, Van Thiel DH, Borle AB. Oxygen free radical formation by rat hepatocytes during postanoxic reoxygenation: scavenging effect of albumin. Am J Physiol 1994; 266:G451-G458.
14. Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge MC. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion. Clin Sci 1998; 96:459-465.
15. Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89:7674-7677.
16. Jorgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb Res 1980; 17:13-18.
17. Jorgensen KA, Stoffersen E. Heparin like activity of albumin. Thromb Res 1979; 16:569-574.
18. Dowiko JP, Nompleggi DJ. Role of albumin in human physiology and pathophysiology. J Parenter Enter Nut 1991; 15:484-487.
19. Demling RH. Effect of plasma and interstitial protein content on tissue oedema formation. Curr Stud Hematol Blood Trans 1986; 53:36-52.
20. Zoellner H, Hofler M, Beckmann R, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 1996; 109:2571-2580.
21. Zoellner H, Hou JY, Lovery M, et al. Inhibition of microvascular endothelial apoptosis in tissue explants by serum albumin. Microvascular Res 1999; 57:162-173.
22. von Hoegen I, Waller C. Safety of human albumin based on spontaneously reported serious events. Crit Care Med 2001; 29:994-996.
23. Rothschild MA, Oratz M, Schreiber SS. Albumin synthesis. N Engl J Med 1972; 286:816-820.
24. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997; 78:974-983.
25. Kilian J, Spilker D, Borst R. Effect of 6% hydroxyethyl starch, 4.5 % dextran 60 and 5.5% oxypolygelatine on blood volume and circulation in human volunteers. Anaethesist 1975; 24:193-197.
26. Lamke LO, Liljedahl SO. Plasma volume expansion after infusion of various plasma expanders. Resuscitation 1976; 5:93-102.
27. Lazrove S, Waxman K, Shippy C. Hemodynamic blood volume and oxygen transport responses to albumin and hydroxyethyl starch infusions in critically ill post operative patients. Crit Care Med 1980; 8:302-306.
28. Metcaff W, Papadopoulos A, Talano R. Clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet 1970; 131:255-267.
29. Solanke TF, Khwaja MS, Madojemu EI. Plasma volume studies with four different plasma volume expanders. J Surg Res 1971; 11:140-143.
30. Thompson WL, Walton RP. Circulatory responses to intravenous infusions of hydroxyethyl starch solutions. J Pharmacol Exp Ther 1964; 146:359-364.
31. Lee WH, Cooper N, Weidner MG. Clinical evaluation of a new plasma expander: hydroxyethyl starch. J Trauma 1968; 8:381-393.
32. Thompson WL, Fukushima T, Rutherford RB, Walton RP. Intravascular persistence, tissue shortage and excretion of hydroxyethyl starch. Surg Gynecol Obstet 1970; 131:965-972.
33. Haupt MT, Rackow EC. Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin and saline solutions. Crit Care Med 1982; 10:159-162.
34. Yacobu A, Stoll RG, Sum CY. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982; 22:206-212.
35. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritis after hydroethyl starch infusion therapy: a result of long term storage in cutaneous nerves. Br J Dermatol 1997; 136:553-559.
36. Botcher U, Georgieff M, Vogt NH. Assessment of the safety and tolerance of 6% hydroxyethyl starch (200/0.5) solution: a randomized, controlled epidemiology study. Anesth Analg 1998; 86:850-855.
37. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001; 15:316-321.
38. Boldt J, Lehmann A, Rompert R, Haisch G, Isgro F. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2000; 14:264-268.
39. Gallandat Huet RC, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 2000; 47:1207-1215.
40. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. All medium starches are not the same: influence of the degree of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 1996; 36:450-455.
41. Treib J, Haass A, Pindur G, et al. Influence of low molecular weight hydroxyethyl starch (HES 40/0.5-0.55) on hemostasis and hemorheology. Haemostasis 1996; 26:258-265.
42. Strauss RG, Stump DC, Henriksen RA. Hydroxyethyl starch accentuates von Willenbrand's disease. Transfusion 1985; 25:235-237.
43. Strauss RG, Stump DC, Henrikson RA, Saunders R. Effects of hydroxyethyl strach on fibrinogen, fibrin clot formation and fibrinolysis. Transfusion 1985; 25:230-234.
44. Stump DC, Strauss RG, Henrikson RA, Peterson RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25:349-354.
45. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357:911-916.
46. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmoticnephrosis- like lesions in kidney transplantation. Lancet 1993; 342:248-249.
47. Vogt NH, Botcher U, Lerch G, Lindner KH, Georgieff M. Large-dose administration of 6% hydroxyethyl starch 200/0.5 total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996; 83:262-268.
48. Coronel B, Mercatello A, martin X, Lefrancois N. Hydroxyethylstarch and renal function in kidney transplant recipients. Lancet 1997; 349:884.
49. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrol Dial Transp 1999; 14:1517-1520.
50. Baron JF. Adverse effects of colloids on renal function. In: Vincent JL, ed. Yearbook of Intensive Care and Emergency Medicine. Heidelberg: Springer, 2000:486-493.
51. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977; 1:466-469.
52. Laxenaire MC, Charpentier C, Feldman L. Anaphylactoid reactions to colloid volume substitutes:incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim 1994; 13:301-310.
53. London MJ, Ho JS, Triedman JK, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989; 97:785-797.
54. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil H. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989; 17:394-398.
55. Mishler JM, Parry ES, Sutherland BA, Bushrod JR. A clinical study of low molecular weight hydroxyethyl starch, a new plasma expander. Br J Clin Pharm 1979; 7:619-622.
56. Mardel SN, Saunders FM, Allen H, et al. Reduced quality of clot formation with gelatin-based plasma substitutes. Br J Anaesth 1998; 80:204-207.
57. Shoemaker WC. Comparison of the relative effectiveness of whole blood transfusions and various types of fluid therapy in resuscitation. Crit Care Med 1976; 4:71-78.
58. Arthurson G, Wallenius G. The renal clearance of dextran of different molecular sizes in normal humans. Scand J Clin Lab Invest 1964; 16:81-86.
59. Arthurson G, Granath K, Thoren L, Wallenius G. The renal excretion of LMW dextran. Acta Clin Scand 1964; 127:543-551.
60. Atik M. Dextran-40 and dextran-70, a review. Arch Surg 1967; 94:664-667.
61. Lewis JH, Szetol LF, Beyer WL. Severe hemodilution with hydroxyethyl starch and dextrans. Arch Surg 1966; 93:941-950.
62. Aberg M, Hedner V, Bergentz S. Effect of dextran on factor VIII and platelet function. Ann Surg 1979; 189:243-247.
63. Data JL, Nies AS. Dextran 40. Ann Intern Med 1974; 81:500-504.
64. Cohn JN, Luria MH, Daddario RC. Studies in clinical shock and hypotension. V. Hemodynamic effects of dextran. Circulation 1967; 35:316-326.
65. Gallus AS, Hirsch J, O'Brien SE. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976; 235:1980-1984.
66. Diomi P. Studies on renal tubular morphology and toxicity after large doses of dextran-40 in the rabbit. Lab Invest 1970; 22:355-360.
67. Feest TG. Low molecular weight dextran: a continuing cause of acute renal failure. Br Med J 1976; 2:1300.
68. Mailoux L, Swartz CD, Capizzi R, et al. Acute renal failure after administration of LMW dextran. N Engl J Med 1967; 277:1113-1118.
69. Matheson NA, Diomi P. Renal failure after the administration of dextran 40. Surg Gynecol Obstet 1970; 131:661-668.
70. Ferraboli R, Malheiro PS, Abdulkader RC, Yu L, Sabbaga E, Burdmann EA. Anuric acute renal failure caused by dextran 40 administration. Ren Fail 1997; 19:303-306.